Analysts Issue Forecasts for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA)

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities research analysts at Wedbush issued their Q3 2024 earnings per share (EPS) estimates for Oruka Therapeutics in a research note issued on Thursday, September 12th. Wedbush analyst D. Nierengarten expects that the company will earn ($0.20) per share for the quarter. Wedbush has a “Strong-Buy” rating on the stock. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.99) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.14) EPS, FY2026 earnings at ($1.53) EPS, FY2027 earnings at ($2.17) EPS and FY2028 earnings at ($2.92) EPS.

Separately, Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research note on Friday. They issued a “buy” rating and a $40.00 price target on the stock.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $24.89 on Monday. Oruka Therapeutics has a 52-week low of $18.72 and a 52-week high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.